We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 12 for:    darpin
Previous Study | Return to List | Next Study

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03418532
Recruitment Status : Terminated (Sponsor's decision)
First Posted : February 1, 2018
Last Update Posted : May 29, 2020
Information provided by (Responsible Party):
Molecular Partners AG

Brief Summary:

The purpose of this study is to assess the anti-tumor efficacy, safety, tolerability, pharmacokinetics (PK), immunogenicity and biological activity of the MP0250 DARPin® drug candidate in combination with osimertinib orally once daily (o.d.), when administered to patients with EGFR mutated, advanced, non squamous NSCLC after tumor progression on osimertinib and on or after the most recent therapy.

MP0250 is a multi-DARPin® protein with three specificities, able to simultaneously neutralize the activities of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and also to bind to human serum albumin (HSA) to give an increased plasma half-life and potentially enhanced tumor penetration.

Condition or disease Intervention/treatment Phase
EGFR-mutated NSCLC (Disorder) Combination Product: MP0250 DARPin® drug candidate, Osimertinib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib
Actual Study Start Date : March 22, 2018
Actual Primary Completion Date : August 30, 2019
Actual Study Completion Date : April 24, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Osimertinib

Arm Intervention/treatment
Experimental: single arm
MP0250 DARPin® drug candidate (6 mg/kg or 8 mg/kg or 12 mg/kg, infusion) on day 1 of each 21 day cycle. Osimertinib according to label
Combination Product: MP0250 DARPin® drug candidate, Osimertinib
Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal

Primary Outcome Measures :
  1. Estimate the objective response rate (ORR) [ Time Frame: 6 months ]
    Tumor response will be assessed based on RECIST 1.1 by using CT or MRI

Secondary Outcome Measures :
  1. Incidence and severity of treatment-emergent adverse events (TEAEs) graded according to CTCAE, v4.03. [ Time Frame: 15 months ]
    number of patients with AE/SAE on the base of CTCAE (version 4.03)

  2. progression free survival (PFS) [ Time Frame: 12 months ]
    PFS according to RECIST 1.1

  3. duration of response (DOR) [ Time Frame: 9 months ]
    DOR according to RECIST 1.1

  4. overall survival (OS) [ Time Frame: 24 months ]
    time from the date of first dose of MP0250 until death from any cause or until 1 year for all patients

  5. time to response (TTR) [ Time Frame: 4 months ]
    TTR according to RECIST 1.1

  6. Incidence of anti-drug (MP0250) antibody formation [ Time Frame: 15 months ]
    determined as titer of anti-drug antibodies

  7. pharmacokinetics [ Time Frame: 15 months ]

  8. pharmacokinetics [ Time Frame: 15 months ]

  9. pharmacokinetics [ Time Frame: 15 months ]

  10. pharmacokinetics [ Time Frame: 15 months ]

Other Outcome Measures:
  1. biomarkers in tissue [ Time Frame: 12 months ]
    biomarkers associated with response or resistance to MP0250, HGF by IHC

  2. biomarkers in blood [ Time Frame: 12 months ]
    biomarkers associated with response or resistance to MP0250, HGF by ELISA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed metastatic or unresectable locally advanced non-squamous NSCLC with documented EGFR mutation-positive disease
  2. Radiologically documented disease progression on previous osimertinib treatment.
  3. Radiologically documented disease progression on or after most recent antitumor therapy.
  4. Measurable disease according to RECIST 1.1.
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 2.
  6. Men and women ≥18 years old on the day of signing informed consent.
  7. Adequate hematological, hepatic and renal function prior to first dose
  8. Serum albumin concentration ≥30 g/L
  9. Potassium and magnesium within normal range

Exclusion Criteria:

  1. Necrotic tumors or tumors close to large blood vessels that may impose an increased bleeding risk when treated with anti-VEGF agents.
  2. Second malignancy that is currently clinically significant or required active intervention during the period of 12 months prior to Screening, except early stage non-melanoma skin cancer treated with curative intent.
  3. Known pre-existing interstitial or inflammatory lung disease.
  4. Clinical signs of or documented leptomeningeal carcinomatosis. Features such as headache, nuchal rigidity, and photophobia may indicate meningeal involvement.
  5. Known brain metastases who are clinically unstable
  6. Prohibited anti-NSCLC therapies and not having recovered from related AEs to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤1
  7. Any investigational drug within 28 days prior to study treatment.
  8. Current participation in any other interventional clinical study (except survival follow up).
  9. Neuropathy as residual toxicity after prior antitumor therapy Grade >2
  10. Patients taking medications that have the potential to prolong the QT interval
  11. Significant cardiac abnormalities
  12. Uncontrolled hypertension
  13. Significant risk for bleeding
  14. Active or recent thrombolic events

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03418532

Layout table for location information
United States, Arizona
Scottsdale Healthcare Hospitals
Scottsdale, Arizona, United States, 85258
United States, California
City of Hope - Comprehensive Cancer Center
Duarte, California, United States, 91010
University of California
San Diego, California, United States, 92093
UCLA Medical Center
Santa Monica, California, United States, 90404
United States, District of Columbia
Georgetown University
Washington, District of Columbia, United States, 20057
United States, Florida
Florida Hospital
Orlando, Florida, United States, 32803
United States, North Carolina
Duke Cancer Institute
Durham, North Carolina, United States, 27710
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Oncology Consultants
Houston, Texas, United States, 77030
Sponsors and Collaborators
Molecular Partners AG
Layout table for additonal information
Responsible Party: Molecular Partners AG
ClinicalTrials.gov Identifier: NCT03418532    
Other Study ID Numbers: MP0250-CP202
First Posted: February 1, 2018    Key Record Dates
Last Update Posted: May 29, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Molecular Partners AG:
EGFR mutated
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action